scholarly journals ANTIMICROBIAL ACTIVITY OF DALBAVANCIN AGAINST GRAM-POSITIVE BACTERIA ISOLATED FROM PATIENTS WITH INFECTIVE ENDOCARDITIS FROM THE UNITED STATES AND EUROPE (2016-2020): RESULTS FROM THE INTERNATIONAL DALBAVANCIN EVALUATION OF ACTIVITY (IDEA) PROGRAM

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A510
Author(s):  
Helio Sader ◽  
Rodrigo Mendes ◽  
Streit Streit ◽  
Cecilia Carvalhaes ◽  
Mariana Castanheira
Keyword(s):  
United States ◽  
Antimicrobial Activity ◽  
Infective Endocarditis ◽  
The United States ◽  
Gram Positive ◽  
Gram Positive Bacteria

scholarly journals Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States

2008 ◽  
Vol 52 (7) ◽  
pp. 2383-2388 ◽  
Author(s):  
Deborah C. Draghi ◽  
Bret M. Benton ◽  
Kevin M. Krause ◽  
Clyde Thornsberry ◽  
Chris Pillar ◽  
...  
Keyword(s):  
United States ◽  
The United States ◽  
Clinical Isolates ◽  
Surveillance Study ◽  
Coagulase Negative Staphylococci ◽  
Gram Positive ◽  
Gram Positive Bacteria ◽  
Serious Infections ◽  
Wide Range ◽  
Vancomycin Resistant

ABSTRACT Telavancin is an investigational, rapidly bactericidal lipoglycopeptide antibiotic that is being developed to treat serious infections caused by gram-positive bacteria. A baseline prospective surveillance study was conducted to assess telavancin activity, in comparison with other agents, against contemporary clinical isolates collected from 2004 to 2005 from across the United States. Nearly 4,000 isolates were collected, including staphylococci, enterococci, and streptococci (pneumococci, beta-hemolytic, and viridans). Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range, 0.03 to 1.0 μg/ml), independent of resistance to methicillin or to multiple agents. Telavancin activity was particularly potent against all streptococcal groups (MIC90s, 0.03 to 0.12 μg/ml). Telavancin had excellent activity against vancomycin-susceptible enterococci (MIC90, 1 μg/ml) and was active against VanB strains of vancomycin-resistant enterococci (MIC90, 2 μg/ml) but less active against VanA strains (MIC90, 8 to 16 μg/ml). Telavancin also demonstrated activity against vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus strains (MICs, 0.5 μg/ml to 1.0 μg/ml and 1.0 μg/ml to 4.0 μg/ml, respectively). These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms.

scholarly journals Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

2003 ◽  
Vol 47 (5) ◽  
pp. 1689-1693 ◽  
Author(s):  
Ian A. Critchley ◽  
Renée S. Blosser-Middleton ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
Daniel F. Sahm ◽  
...  
Keyword(s):  
United States ◽  
Outpatient Care ◽  
Antimicrobial Agents ◽  
The United States ◽  
Multidrug Resistant ◽  
Gram Positive ◽  
Gram Positive Bacteria ◽  
Oxacillin Resistance ◽  
Positive Spectrum

ABSTRACT The activity of daptomycin was assessed by using 6,973 gram-positive bacteria isolated at 50 United States hospitals in 2000 and 2001. Among the isolates of Streptococcus pneumoniae (n = 1,163) collected, the rate of penicillin resistance was 16.1%; rates of oxacillin resistance among Staphylococcus aureus isolates (n = 1,018) and vancomycin resistance among Enterococcus faecium isolates (n = 368) were 30.0 and 59.5%, respectively. Multidrug-resistant (MDR) phenotypes (isolates resistant to three or more different chemical classes of antimicrobial agents) accounted for 14.2% of S. pneumoniae isolates, 27.1% of S. aureus isolates, and 58.4% of E. faecium isolates. For all gram-positive species tested, MICs at which 90% of the isolates tested were inhibited (MIC90s) and MIC ranges for directed-spectrum agents (daptomycin, quinupristin-dalfopristin, and linezolid) were identical or highly similar for isolates susceptible or resistant to other agents or MDR. Daptomycin had a MIC90 of 0.12 μg/ml for both penicillin-susceptible and -resistant isolates of S. pneumoniae. Against oxacillin-resistant S. aureus daptomycin had a MIC90 of 0.5 μg/ml, and it had a MIC90 of 4 μg/ml against both vancomycin-susceptible and -resistant E. faecium. The MIC90s for daptomycin and other directed-spectrum agents were unaffected by the regional or anatomical origin of isolates or patient demographic parameters (patient age, gender, and inpatient or outpatient care). Our results confirm the gram-positive spectrum of activity of daptomycin and that its activity is independent of susceptibility or resistance to commonly prescribed and tested antimicrobial agents. This study may serve as a baseline to monitor future changes in the susceptibility of gram-positive species to daptomycin following its introduction into clinical use.

scholarly journals 1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S323-S323
Author(s):  
Helio S Sader ◽  
Rodrigo E Mendes ◽  
Michael A Pfaller ◽  
Robert K Flamm
Keyword(s):  
United States ◽  
Infective Endocarditis ◽  
The United States ◽  
Vitro Activity ◽  
Surveillance Program ◽  
In Vitro Activity ◽  
Research Support ◽  
Gram Positive ◽  
Medical Centers

Abstract Background The management of endocarditis requires aggressive and prolonged antimicrobial treatment. Dalbavancin (DALBA) has demonstrated potent in vitro activity against Gram-positive (GP) organisms commonly responsible for endocarditis and is being evaluated for treatment of complicated bacteremia and infective endocarditis. Methods A total of 626 GP organisms were collected from patients with a diagnosis of bacterial endocarditis in the United States (n = 222) and Europe (n = 404) from 2007 to 2017 via the SENTRY Antimicrobial Surveillance Program and were tested for susceptibility (S) against DALBA and comparators by CLSI broth microdilution. Results The most common organisms were S. aureus (48.4%), E. faecalis (EF; 19.6%), and viridans group streptococci (VGS; 12.5%). DALBA and daptomycin (DAPTO) showed complete activity (100.0%S) against S. aureus, but DALBA MICs were 4- to 8-fold lower (table). Linezolid (LZD) and teicoplanin were also active against all SA; whereas vancomycin (VAN) and trimethoprim–sulfamethoxazole were active against 99.7% of isolates. Ceftaroline (CPT) exhibited potent activity against methicillin-susceptible S. aureus (MSSA; MIC90, 0.25 mg/L; 100.0%S) and inhibited 78.4% of methicillin-resistant S. aureus (MRSA) isolates at ≤1 mg/L. All EF isolates were S to ampicillin, DAPTO, and LZD, whereas 97.6% (120/123) of isolates were S to DALBA (MIC90, 0.06 mg/L) and 96.7%S to VAN (MIC90, 2 mg/L). Against EF, DALBA MIC values were 16- to 32-fold lower than DAPTO and VAN. All VGS and coagulase-negative staphylococcal (CoNS) isolates were S to DALBA, DAPTO, VAN, and LZD, and the highest CPT MICs were 0.5 mg/L for VGS and 4 mg/L for CoNS (93.5% inhibited at ≤1 mg/L). Against E. faecium (EFM), 65.7% of isolates were inhibited at ≤0.25 mg/L of DALBA and 62.9% were VAN-S. All EFM were S to DAPTO and LNZ. β-Hemolytic streptococci (BHS) was S to most antimicrobial agents, and only 66.7% of S. pneumoniae (SPN) isolates were PEN-S at ≤0.06 mg/L. Conclusion DALBA exhibited potent in vitro activity against a large collection of GP isolates recovered from patients with endocarditis in the United States and Europe medical centers. These results support further investigations to determine the role of DALBA in the treatment of infective endocarditis. Disclosures H. S. Sader, Allergan: Research Contractor, Research support. R. E. Mendes, Allergan: Research Contractor, Research support. M. A. Pfaller, Allergan: Research Contractor, Research support. R. K. Flamm, Allergan: Research Contractor, Research support.

scholarly journals Enaminone-Derived Pyrazoles with Antimicrobial Activity

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Mashooq Ahmad Bhat ◽  
Mohamed A. Al-Omar ◽  
Ahmed M. Naglah ◽  
Abdul Arif Khan
Keyword(s):  
Antimicrobial Activity ◽  
Gram Negative Bacteria ◽  
Significant Activity ◽  
Disc Diffusion ◽  
Initial Screening ◽  
Gram Positive ◽  
Gram Negative ◽  
Disc Diffusion Assay ◽  
Gram Positive Bacteria ◽  
Diffusion Assay

A series of pyrazoles derived from the substituted enaminones were synthesized and were evaluated for antimicrobial activity. All the compounds were characterized by the spectral data and elemental analysis. The synthesized compounds were initially screened for their antimicrobial activity against ATCC 6538, NCTC 10400, NCTC 10418, and ATCC 27853. During initial screening, compounds (P1, P6, and P11) presented significant antimicrobial activity through disc diffusion assay. These compounds were further evaluated for antimicrobial activity at different time points against Gram-positive and Gram-negative bacteria and presented significant activity for 6 hours. The activity was found to be greater against Gram-positive bacteria. In contrast at 24 hours, the activity was found only against Gram-positive bacteria except compound (P11), showing activity against both types of bacteria. Compound (P11) was found to have highest activity against both Gram-positive and Gram-negative bacteria.

Antimicrobial Activity of Isopteropodine

2005 ◽  
Vol 60 (5-6) ◽  
pp. 385-388 ◽  
Author(s):  
Rubén García ◽  
Cesia Cayunao ◽  
Ronny Bocic ◽  
Nadine Backhouse ◽  
Carla Delporte ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Antibacterial Activity ◽  
Gram Positive ◽  
Uncaria Tomentosa ◽  
Gram Positive Bacteria

Bioassay-directed fractionation for the determination of antimicrobial activity of Uncaria tomentosa, has led to the isolation of isopteropodine (0.3%), a known Uncaria pentacyclic oxindol alkaloid that exhibited antibacterial activity against Gram positive bacteria.

scholarly journals Corrigendum

2017 ◽  
Vol 4 (6) ◽  
pp. 193-193
Keyword(s):  
United States ◽  
The United States ◽  
Original Text ◽  
The European Union ◽  
Broth Microdilution ◽  
Alternative Treatments ◽  
Gram Positive ◽  
Baseline Activity ◽  
Broth Microdilution Method ◽  
Complicated Skin

Das B, Sarkar C, Das D et al. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017 Mar; 4(2): 49–73. DOI: 10.1177/2049936117690501 The authors wish to highlight the following corrections, which should have appeared in the original text: 1.  Page 49, Abstract, lines 4–5: Telavancin is approved for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in the United States when alternative treatments are not available. In Russia and Canada, telavancin is approved for both complicated skin and skin-structure infections (cSSSI) and HABP/VABP. 2.  Page 50, right panel, para 2, lines 15–18: Revised per telavancin label based on latest PI and EMA (also pasted below). In the United States, telavancin is approved in adults for the treatment of cSSSI due to susceptible Gram-positive pathogens. In addition, telavancin is approved for HABP/VABP when alternative treatments are not suitable. In Canada and Russia, telavancin is approved for Gram-positive pathogens for the treatment of patients with cSSSI and HABP/VABP. In the European Union, telavancin is approved for the treatment of nosocomial pneumonia, known or believed to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternative medicines are unsuitable. 3.  Page 51, right panel, para 1, lines 1–6: Per the latest (2016) telavancin PI, HABP/VABP indication for telavancin should be included. 4.  Page 51, Figure 1 caption: The hydrophilic nature of telavancin contributes to its half-life. 5.  Page 53, left panel, para “In vitro activity”, lines 5–8: As per the following (newer) article, which states that “Telavancin MIC is 16-32 fold lower than vancomycin against MRSA.” Mendes RE, Flamm RK, Farrell DJ, et al. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin. J Chemother 2015; 28: 83–88. DOI: 10.1179/1973947815Y.0000000050 6.  Page 53, right panel, para 1, lines 11–16: Per the Mendes et al. (2015) article listed above, telavancin minimum inhibitory concentration (MIC) is 16- to 32-fold lower than vancomycin against MRSA. 7.  Page 54, Table 1: These MIC values were estimated using old methods. Revise the MIC values based on the references for new MIC methods (see below). Farrell DJ, Mendes RE, Rhomberg PR, et al. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 2014; 58(9): 5547–5551. DOI: 10.1128/AAC.03172-14 8.  Page 61, right panel, para “ATTAIN trials (ATTAIN 1 and 2)”, lines 9–12: The ATTAIN trials did not include patients with “healthcare-associated pneumonia,” therefore, any mention of this is not correct.

Sign in / Sign up

Export Citation Format

Share Document